![(3R)-3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]piperidine in PDB entry 3hcm, assembly 1, side view.](https://www.ebi.ac.uk/pdbe/static/entry/3hcm_entity_3_side_image-200x200.png "Homo dimeric assembly 1 of PDB entry <span class='highlight'>3hcm</span> contains 2 copies of <span class='highlight'>(3R)-3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]piperidine</span>. Side view.")
![(3R)-3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]piperidine in PDB entry 3hcm, assembly 1, top view.](https://www.ebi.ac.uk/pdbe/static/entry/3hcm_entity_3_top_image-200x200.png "Homo dimeric assembly 1 of PDB entry <span class='highlight'>3hcm</span> contains 2 copies of <span class='highlight'>(3R)-3-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]piperidine</span>. Top view.")
Environment details NEW
S45 94 bound to chain A
The above 2D and 3D (Mol*) views of ligand interactions use quaternary structure derived from the PDB entry.
Please note:
Please note:
- Some chain IDs in the tooltip are followed by a number in square brackets. This number corresponds to the operation ID (mmCIF ‘oper_expression’) used to transform the chain.
- The structure seen in Mol* (3D view) was protonated using ChimeraX.
- Interactions were calculated using Arpeggio (see details for interaction types).
- The colour scheme used is consistent with Clustal X.